ABBOTT LABORATORIES

(ABT)
  Report
Delayed Nyse  -  05/26 04:03:39 pm EDT
114.87 USD   +1.48%
12:47pAbbott Laboratories Recalls Dragonfly OpStar Imaging Catheter on Concerns Loose Marker Band Could Cause Harm
MT
11:35aAbbott Laboratories Recalls Dragonfly Opstar Imaging Catheter As Potential Loose Market Band Could Cause Patient Harm
MT
05/25TIMELINE : Baby formula crunch in U.S. forces scramble to boost supplies
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories Secures FDA Clearance for Ensite Cardiac Mapping Platform

01/12/2022 | 09:43am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 1.48% 114.87 Delayed Quote.-18.38%
ON SEMICONDUCTOR CORPORATION 5.49% 59.33 Delayed Quote.-12.65%
All news about ABBOTT LABORATORIES
12:47pAbbott Laboratories Recalls Dragonfly OpStar Imaging Catheter on Concerns Loose Marker ..
MT
11:35aAbbott Laboratories Recalls Dragonfly Opstar Imaging Catheter As Potential Loose Market..
MT
05/25TIMELINE : Baby formula crunch in U.S. forces scramble to boost supplies
RE
05/25Abbott to release elecare amino acid-based formulas to help meet critical patient need
AQ
05/25MARKETSCREENER'S WORLD PRESS REVIEW : May 25, 2022
05/25Abbott to Release Limited Quantities of EleCare Formula Milk
MT
05/25Danone, Reckitt race to ramp up US baby formula supply amid shortage
RE
05/24Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need
PR
05/24Abbott to Release EleCare® Amino Acid-Based Formulas to Help Meet Critical Patient Need
CI
05/24U.S. FTC launches inquiry into infant formula shortage
RE
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2022 41 813 M - -
Net income 2022 6 805 M - -
Net Debt 2022 4 167 M - -
P/E ratio 2022 30,7x
Yield 2022 1,67%
Capitalization 201 B 201 B -
EV / Sales 2022 4,91x
EV / Sales 2023 4,88x
Nbr of Employees 113 000
Free-Float 87,5%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 114,87 $
Average target price 137,43 $
Spread / Average Target 19,6%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Glenn Fletcher Tilton Independent Director
William A. Osborn Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES-18.38%198 189
MEDTRONIC PLC2.02%141 586
BECTON, DICKINSON AND COMPANY2.60%71 882
HOYA CORPORATION-19.84%39 348
BAXTER INTERNATIONAL INC.-12.41%37 860
AMERISOURCEBERGEN CORPORATION15.19%32 314